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PARATHYROID IIORMONE-RELATED PEI'TIUI: (PTHrP) 1NTEKAC' PIONS WITH RENAL RENIN AND EDRF SYSTEMS. U. SIMEONI, C . SAUSSINE, T . MASSFELDER, M.J. MUSSO, M. FISCIiGACtl, J . GElSERT attd J . J . HELWIG. Labo P l 1 9 i u R @ n d e , Hunpicen C i u A -U.L.P. S L m~b u u n g , Fhrtncc.
PTHrP, t h e primary c a u s a t i v e agent of the hyprrcalcemia a s s o c i a t e d w i t h humoral malignancy, i s so-named f o r i t s a b i l i t y t o a c t a s a PTH a g o n i s t i n kidney and bone. Like PTH, PTHrP i s a l s o hypotensive and v a s o r e l a x a n t . But, u n l i k e P'TII, PTtlrP nlRNA has bcen l o c a l i z e d i n nornlal f e t a l and a d u l t t i s s u e s i n c l u d i n g v a s c u l a r t i s s u e . Thus, PTHrP may s e r v e a s a l o c a l r e g u l a t o r of the Iren~odynnmic of devrlupping and a d u l t kidney. I n l i g h t of t h i s p o s s i b i l i t y we demonstrated e a r l i e r t h e presence of r e c e p t o r s responsive t o 1"I'HrP i n preglotnerular v e s s e l s and i t s vasorelaxant a c t i o n i n t h e i s o l a t e d perfused kidney (IPK) of r a t . I n t h i s work, we show t h a t L25oM PTHrP increased r e n i n r e l e a s e (RK) from non f i l t e r i n g IPK of r a t perfused a t c o n s t a n t flow and s t a b i l i z e d p r e s s u r e (70 mm H g ) by 161Z. IJTHrP reversed the i n h i b i t i n g e f f e c t o i h y p e r c a l c i c media (2mM ca2+) and 20nM RAY-K8644 (Ca channel opener). I n r a b b i t I1' K p r r c o n s t r i c t e d with norepinephrine, l p M Nw-Nitro-L-Arg llenzyl E s t e r (NARE), an i n h i b i t o r of EIIKF s y n t h e s i s decreased by 80-902 tltc r e n a l r c l n x a t i o o i n response t o LOPM a c e t y l c h o l i n e . P a r a l l e l y , NAUli decreased by 20 t o 40% the r e l a x a t i o n i n response t o 87nM of PTHrl'. Conclusion: 1) PTllrP s t i m u l a t e s RK independently from macula densa and baroreceptor mechanisms by a Ca-dependent p r o c c s s ; 2 ) r e n a l v a s o d i l a t a t i o n i n response t o L'TllrP probably involves i n a d d i t i o n t o CAMP, an EDRPdependent process. Together with t h e presence of I"l'llrP mKNA i n sniootli muscle c e l l s shown i n o t h e r r e s p e c t s , t h e s e r e s u l t s support t h e view t h a t PTHrP c o n t r i b u t e s l o c a l l y t o r e n a l blood flow r e g u l a t i o n . In o r d e r t o t e s t t h e hypothesis t h a t changes i n pulmonary compliance a f f e c t ANF levels,we measured t h e c o n c e n t r a t i o n s of ANF sequentiall y i n 24 neonates.Al1 i n f a n t s were mechanically v e n t i l a t e d f o r sever e HMD and received m u l t i p l e doses (3) (4) (5) of porcine S (Curosurf).The BW was 1654k570gr (mean LSD) and t h e G A 3112.8 weeks.ANF concentrat i o n s were high on day 1 (206i198pgr/ml) before S a d m i n i s t r a t i o n , b u t decreased on day 2(192t123pgr/ml),in c o n t r a s t t o s t a t i s t i c a l l y s i g n if i c a n t e l e v a t i o n s seen i n neonates with HMD not t r e a t e d o r t r e a t e d with a s i n g l e dose of S.ANF f u r t h e r declined on day 4(93182pgr/ml). There were n o t s i g n i f i c a n t d i f f e r e n c e s i n ANF l e v e l s between neonates r e c e i v i n g high (600mg/kgr) and low (3OQrg/kgr)doses of S . h r results sugwst t h a t a s lung compliance i n c r e a s e d , a f t e r S a d~n i n i s t r a t i o n , i n t r a t h o r ac i c p r e s s u r e i n c r e a s e d , t h e r e b y decreasing Venus r e t u r n , a t r i a l s t r e c h and ANF s e c r e t i o n . B e f o r e S a d m i n i s t r d t i o n , t h e ANF c o n c e n t r a t i o n s increased fro111 a level of 98pgrlml 1-2hours a f t e r b i r t h t o a ttiaxintum of 426 p g r l a l a t t h e age of 12-24hour8, a s seen by o t h e r s . F a c t o r s ass o c i a t e d with higher ANF l e v e l s were t h e presence of PDA,and water r e t e n t i o n (p<.05).However,we were unable t o d e t e c t any s i g n i f i c a n t c o r r e l d t i o n between ANF l e v e l s and c r e a t i n i n e c l e a r a n c e , FeNa, R F I o r r a t i o water i n t a k e t o u r i n e output i n t h i s population. The hypo~hesis to be tested is that persistence of the fetal zone of the adrenal gland after psetern~ birth is due to continuitig stimulation by ACTH. 22 infants of menn gestiition 27.6 weeks and mcan birth wetght 946g were studied longitudinally between 170-360 days postconception;rl age (PCA). Ctrculating DHEAS and its t1rin;lry metubolites were used its a mensure of ;~dretial fetal zone function. Menn plasma Dl-IEAS fell form 12.3 pmol 1.' at 176 days PCA to < 1.0 p o l 1' at 350 days PCA. During the same period the pl;rsm;t ACTfI increased from 9 pg rill-' to 48 pg ml-I. After tern1 (280 days) the plasni;~ DHEAS became barely detectable. 111 individual babies ttri~~ary excretion of Dl IEAS metribolites remained elevated but declined between 280-300 days PCA. Dex;~metIi;tsotre given to one itihti1 completely suppressed pliistnir cortisol and ACTH, but the plasma DHEAS and its metabolites in [lie urine were not suppressed to tlic sanie extent. We conclude that the adrelial fet:tl zone in preterni inf;ints continues to secrete 3P-OH-Sene steroids following delivery i u~d after tern1 these decline. Because of the observed changes in plnsm;t ACI'II and DliEAS and the ktilure of dex;rtncth:isone to fully suppress [lie fctnl zone it is likely that ACTH is trot the sole regul;ttor of the fetal zone of the adrenal gl;ind in preternl inliints. 
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FATE OF OROGASTRICALLY ADMINISTERED INSULIN-LIKE GROWTH

I G F ' s a r e s t i m u l a t o r s o f m i t o s i s a n d may b e o f i m p o r t a n c e i n t h e r e g u l a t i o n o f i n t e s t i n a l g r o w t h i n t h e n e o n a t e . S i n c e I G F ' s a r e p r e s e n t i n a v a r i e t y o f m i l k s , we t e s t e d t h e h y p o t h e s i s t h a t i n g e s t e d m i l k -b o r n e I G F ' s m i g h t b e a v a i l a b l e t o g a s t r o i n t e s t i n a l ( G I ) t i s s u e s a n d m i g h t a l s o b e a b s o r b e d t o s i t e s d i s t a n t t o t h e GI t r a c t .
R e c o m b i n a n t 1251-IGF-I a n d -11 i n r a t m i l k w e r e g i v e n v i a s t o m a c h t u b e t o s u c k l i n g r a t s . A p p r o x i m a t e l y 4 0 % o f IGF-I o r -I 1 cpm r e m a i n e d i n t h e G I t r a c t a t 3 0 m i n p o s t i n g e st i o n w i t h < 1'; a p p e a r i n g i n most. o t h e r o r g a n s . G e l c h r o m a t o g r a p h y d e m o n s t r a t e d t h a t much o f r a d i o a c t i v i t y p r e s e n t i n GI t r a c t h o r n o g e n a t e s e l u t e d t o g e t h e r w i t h a ut h e n t i c IGF. S i g n i f i c a n t d i f f e r e n c e s w e r e n o t e d i n a m o u n t s o f IGF-I v s -I 1 f o u n d i n G I t i s s u e s a f t e r 3 0 m i n , p a r t i c u l a r l y i n s t o m a c h a n d i n t e s t i n a l w a l l a n d l u m e n . E x o g e n o u s IGF-I r e p r e s e n t e d t w i c e t h e a m o u n t o f I G F -I 1 i n t h e s e t i s s u e s . C o m p e t i t i v e b i n d i n g s t u d i e s c o n f i r m e d t h a t b i n d i n g o f r a d i o a c t i v i t y p r e s e n t i n p e a k s a t 7 . 5 K MW w e r e i d e n t i c a l t o t h o s e o f n a t i v e "!'I-IGF's.
T h e s e s t u d i e s show t h a t m i l k -b o r n e IGF r e m a i n s i n t a c t i n t h e G I t r a c t o f s u c k l i n g r a t s f o r a t l e a s t 30 m i n p o s t i n g e s t i o n .
LOW SERUM GLUCOSE CONCENTRATIONS INDUCE GLUCAGON COUNTERREGULATION IN HEALTHY NEWBORNS. lngemar Swenne, Uwe
Ewald, Jan Gustafsson and Claes-Goran Oslensson*. Depts of Paediatrics, Uppsala University, Uppsala and Endocrinology *, Karolinska Hospital, Stockholm, Sweden.
Before feeding regulatory mechanisms maintain blood glucose concentrations of the newborn to meet the demands of the central nervous system. The role of glucagon in this proccss has been investigated. Healthy, term babies without clinical signs of hypoglycemia were studied. A capillary blood sample was obtained at 3-15 hours (median 6 hours) of age, a second sample 24 hours later and serum concentrations of glucose, insulin and glucagon were measured. Glucose concentrations at the first sampling averaged 2.1 * 0.5 mM (mean f SD; n=51) and were positively correlated with postnatal age. At the second sampling glucose concentrations had increased to 3.0 f 0.5 mM. Glucagon concentrations were 541 f 219 pglml at the first sampling and inversely correlated with glucose concentrations. At the second sampling glucagon concentrations had decreased to 406 + 163 pglml. Insulin concentrations were 12.1 f 2.4 and 10.6 f 2.1 pUlrnl, respectively, and did not correlate with glucose concentrations. In a multiple regression analysis glucose concentrations were inversely correlated with glucagon concentrations and positively correlated with birth weights but not correlated with insulin concentrations o r other neonatal and maternal characteristics. The results suggebt that glucagon is part of normal counterregulalion against hypoglycemia and that nconatal energy stores, as indicated by birth weight, influence the ability to maintain normoglycemia.
